Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit .NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
马萨诸塞州牛顿市，2024年11月26日（环球新闻社）-- 博诺制药股份有限公司。 （纳斯达克：ABOS），一家临床阶段生物制药公司，致力于开发针对毒性可溶性淀粉样蛋白β寡聚体的新型治疗药物，用于治疗阿尔茨海默病。今日宣布，管理层将参加于2024年12月3日下午3点，在第7届Evercore ISI HealthCONx会议上举行的圆桌讨论。
The live webcast may be accessed under the Investors tab on and will be archived for 90 days.
可在投资者选项卡下查看直播网络广播，并将归档保存90天。 ，网址为
About Acumen Pharmaceuticals, Inc.
世锐制药是一家临床阶段的生物制药公司，开发一种新型治疗方法，针对致毒的可溶性淀粉样蛋白β寡聚体，治疗阿尔茨海默病。世锐制药的创始人在AβOs研究方面走在了前沿，越来越多的证据表明它们是阿尔茨海默病病理过程的早期和持续的触发器。目前，世锐制药专注于推进其研究产品候选Sabirnetug（ACU193）在ALTITUDE-AD（NCT06335173）的第2期临床试验中，治疗早期症状的阿尔茨海默病患者，经过了INTERCEPt-AD的第1期试验的积极结果。公司总部设在马萨诸塞州的纽顿市。
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit .
Acumen Pharmaceuticals是一家临床阶段的生物医药公司，正在开发一种针对阿尔茨海默病的毒性可溶性β淀粉样寡聚体的新型治疗方法。Acumen的科学创始人在β淀粉样寡聚体的研究方面率先开展了研究，越来越多的证据表明它们是阿尔茨海默病病理的早期和持续触发剂。Acumen目前专注于推进其研究产品候选物sabirnetug（ACU193），这是一种选择性靶向毒性可溶性β淀粉样寡聚体的人源单克隆抗体，正在进行的ALTITUDE-AD（NCT06335173）Phase 2临床试验中使用于早期症状阿尔茨海默病患者，该试验的Phase 1试验INTERCEPt-AD取得了积极的结果。该公司总部位于马萨诸塞州牛顿市。更多信息，请访问 .
Investors:
Alex Braun
abraun@acumenpharm.com
投资者：
亚历克斯·布劳恩
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
媒体:
AcumenPR@westwicke.com
